John Wagstaff

7PUBLICATIONS
93CO-AUTHORS
Predictive and prognostic markersEpidemiological modellingPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 06, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Georgina V Long, James Larkin, Dirk Schadendorf

|Feb 13, 2024
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial.

Alison Jane Birtle, Robert Jones, John Chester

|Jul 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.

Nicholas D James, Fiona C Ingleby, Noel W Clarke

|Apr 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Nicholas D James, Noel W Clarke, Adrian Cook

|Nov 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez

|Nov 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.

Hannah L Rush, Laura Murphy, Alicia K Morgans

Pageof 2

Frequent Collaborators

4 joint publications

Alison Jane Birtle

4 joint publications

Robert Jones

3 joint publications

Andrew S Protheroe

3 joint publications

Joe M O'Sullivan